2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - New Orleans Theatre A
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Computational Biology, Profiling, Artificial Intelligence (AI), Machine Learning, Biological Processes, Genomics, Immune Mechanism, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

72 Real-time monitoring of circulating tumour DNA through CAR T-cell therapy for early identification of failure and subsequent minimal residual disease-directed intervention

Mark Raymond Dowling, PhD, Sally Hunter Jr, PhD2, Joshua Casan, MD, PhD3, Sushmitha Kannan Jr4, Shafqat Inam, MBBS FRACP FRCPA5, Catelyn Cashion, BMed FRACP FRCPA6, Anthony Jeffrey, MBBS7, Sean McKeague8, Safia Belbachir, MD9, Stephen Boyle10, Thomas Buss, MBBS11, Ella Thompson, PhD12, Jane Oliaro13, P. Joy Ho, MBBS, DPhil, FRACP, FRCPA14, Danielle Blunt, MBBS15, Allison Barraclough, MBBS, BSc, FRACP, FRCPA16, Constantine S. Tam, MD,MBBS17, Andrea Henden, PhD, MBBS, BSc, FRACP, FRCPA18, Emily Blyth, MD, PhD19, Vinay Vanguru, MBBS20, Michael Dickinson, MBBS (Hons), DMedSci FRACP, FRCPA21, Piers Blombery, PhD22
1 Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, The University of Melbourne, Melbourne, Victoria, Australia
2 Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
3 Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, The University of Melbourne, Melbourne, Victoria, Australia
4 Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
5 Alfred Hospital, Melbourne, Victoria, Australia
6 The University of Sydney, Sydney, New South Wales, Australia, Westmead Hospital, Sydney, New South Wales, Australia
7 Royal Prince Alfred Hospital, Sydney, New South Wales, Australia, The University of Sydney, Sydney, New South Wales, Australia
8 Royal Brisbane and Women's Hospital, Brisbane, Australia, The University of Queensland, Brisbane, Australia
9 Fiona Stanley Hospital, Perth, Australia
10 QIMR Berghofer Medical Research Institute, Brisbane, Australia, Royal Brisbane and Women's Hospital, Brisbane, Australia, The University of Queensland, Brisbane, Australia
11 Fiona Stanley Hospital, Perth, Australia
12 Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
13 Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, The University of Melbourne, Melbourne, Victoria, Australia
14 Royal Prince Alfred Hospital, Sydney, New South Wales, Australia, The University of Sydney, Sydney, New South Wales, Australia
15 Royal Adelaide Hospital, Adelaide, South Australia, Australia
16 Fiona Stanley Hospital, Perth, Australia, Monash University, Melbourne, Victoria, Australia
17 Alfred Hospital, Melbourne, Victoria, Australia, Monash University, Melbourne, Victoria, Australia
18 QIMR Berghofer Medical Research Institute, Brisbane, Australia, Royal Brisbane and Women's Hospital, Brisbane, Australia, The University of Queensland, Brisbane, Australia
19 The University of Sydney, Sydney, New South Wales, Australia, Westmead Hospital, Sydney, New South Wales, Australia, Westmead Institute for Medical Research, Sydney, New South Wales, Australia
20 Royal Prince Alfred Hospital, Sydney, New South Wales, Australia, The University of Sydney, Sydney, New South Wales, Australia
21 Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, The University of Melbourne, Melbourne, Victoria, Australia
22 Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, The University of Melbourne, Melbourne, Victoria, Australia

Introduction:  Around half of patients experience disease progression following chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), with the highest risk period being the first three months following infusion. Residual PET activity can be difficult to interpret in this context, due to inflammatory changes that may not represent viable lymphoma. Herein we report a large multi-centre prospective cohort of patients who underwent ctDNA testing for minimal residual disease (MRD) after standard-of-care CAR-T for R/R LBCL. We aimed to evaluate the role of ctDNA in predicting relapse and to identify patients eligible for a ctDNA-guided interventional study of epcoritamab-based therapy post CAR-T (EpLCART, NCT06414148).

Methods: ctDNA MRD was offered as an accredited laboratory-developed test at the Peter MacCallum Cancer Centre. Libraries of ctDNA were prepared using the KAPA HyperCap DS NHL panel NHL-KAPA (Roche Diagnostics). Reporter variants were identified from tissue and/or ctDNA prior to CAR-T infusion. Genomic data were analysed using a modified workflow from ctDNAtools (Alkodsi et al, BioRxiv 2020) including analysis of phased variants.

Results: 365 patients planned for CAR-T consented to prospective ctDNA testing at six centres in Australia between Feb 2024 and Jan 2026. The median age was 66 (range 16–85), 124 (34%) were female. Histologies were high-grade B-cell lymphoma (HGBL) 36 (10%), DLBCL 205 (56%), transformed lymphoma (TL) 96 (26%), and other LBCL 28 (8%). 355 (97%) of patients received axicabtagene ciloleucel (axi-cel); 10 (3%) received tisagenlecleucel (tisa-cel). 206 (56%) received CAR-T as second-line therapy and 159 (44%) as third-line+; 41 (11%) had received prior autologous stem-cell transplant; 217 (59%) were refractory to their most recent systemic therapy.

342 (94%) proceeded to infusion, of which 324 (95%) had baseline (tumour biopsy or ctDNA) and at least one follow-up ctDNA sample available. Baseline samples were archival tumour biopsy in 283 (87%) patients (median 3.7, interquartile range (IQR) 1.7–7.8, range 0.3–100.0 months prior to infusion), ctDNA in 37 (11%), both in 1 (0.3%), bone marrow aspirate 2 (0.6%) and peripheral blood in 1 (0.3%). Reporter variants were identified in 305 (94%) patients (4 technical failures and 15 insufficient reporter variants from baseline sequencing). Median reporter variants 176 (IQR 99–272, range 13–851); median phased variants 55 (IQR 32–84, range 5–258); median sequencing depth 5930x (IQR 3710–7260, range 431–18600x).

At month 1 (M1; D+25–59 post CAR-T infusion) post CART, a total of 290 ctDNA MRD results were reported to the treating clinicians at a median of 17 days (IQR 15–23, range 8–98) from sample receipt. 88 (30%) were ctDNA MRDpos and 202 (70%) MRDneg. Amongst patients in complete metabolic response (CMR), partial metabolic response (PMR), no metabolic response (NMR) or progressive metabolic disease (PMD), the ctDNA MRDpos rates were 34/198 (17%), 27/57 (47%), 5/9 (56%), and 19/20 (95%), respectively. 38 (13%) subsequently enrolled in EpLCART based on M1 ctDNA MRD and PET-CT status. M1 ctDNA MRDpos patients who were observed without intervention had an estimated 12-month progression free survival (PFS) of 19% (9–43%). M1 ctDNA MRD negative patients had a 12-month PFS of 73% (66–80%).

At month 3 (M3; D+60–100 post CAR-T infusion) post CAR-T, a total of 134 ctDNA MRD results were reported: 15 (11%) positive and 119 (89%) negative. Amongst patients in CMR, PMR, NMR or PMD, the ctDNA MRD positive rates were 1/97 (1%), 1/8 (13%), 1/3 (33%), and 10/12 (83%) respectively. Two patients enrolled in EpLCART based on M3 ctDNA MRD and PET-CT status. The 12-month estimated PFS amongst patients who were observed without intervention was not estimable (insufficient numbers) in the M3 ctDNA MRDpos group and 80% (71–89%) in the ctDNA MRDneg group.

Conclusions: Real-time ctDNA monitoring post CAR-T is feasible with rapid turnaround from a centralised laboratory. Those patients without radiologic progression, who are ctDNA MRDpos at between one and three months post infusion are at a high risk of subsequent progression, representing a group (~20% infused) with sufficiently poor prognosis to justify exploratory interventions.

Mark Raymond Dowling, PhD: Novartis - Honoraria; Johnson & Johnson - Honoraria; Roche - Honoraria; Kite/Gilead - Honoraria; Kite/Gilead - Research Funding; AbbVie - Research Funding; AbbVie - Patents & Royalties